AKT2 Human shRNA Plasmid Kit (Locus ID 208)
CAT#: TR320261
AKT2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 4,790.00
货期*
现货
规格
Product images
经常一起买 (2)
AKT2 mouse monoclonal antibody, clone OTI4H7 (formerly 4H7)
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Product Name | AKT2 Human shRNA Plasmid Kit (Locus ID 208) |
Locus ID | 208 |
UniProt ID | P31751 |
Synonyms | HIHGHH; PKBB; PKBBETA; PRKBB; RAC-BETA |
Vector | pRS |
Format | Retroviral plasmids |
Kit Components | AKT2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 208). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
RefSeq | NM_001243027, NM_001243028, NM_001330511, NM_001626, NM_001626.1, NM_001626.2, NM_001626.3, NM_001626.4, NM_001626.5, NM_001243027.1, NM_001243027.2, NM_001243028.1, NM_001243028.2, BC022779, BC032709, BC040028, BC063421, BC120994, BC120995, BM675176, NM_001243027.3, NM_001243028.3, NM_001626.6 |
Summary | This gene is a putative oncogene encoding a protein belonging to a subfamily of serine/threonine kinases containing SH2-like (Src homology 2-like) domains, which is involved in signaling pathways. The gene serves as an oncogene in the tumorigenesis of cancer cells For example, its overexpression contributes to the malignant phenotype of a subset of human ductal pancreatic cancers. The encoded protein is a general protein kinase capable of phophorylating several known proteins, and has also been implicated in insulin signaling. [provided by RefSeq, Nov 2019] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...